- Galena Biopharma (GALE) completes enrollment of the full 45-patient cohort for the Phase 2a clinical trial for GALE-301 (Folate Binding Protein (FBP) peptide immunotherapy). The two arms of the trial consist of HLA-A2-positive patients treated with the FBP peptide plus granulocyte macrophage-colony stimulating factor (GM-CSF) and an observational control group of HLA-A2-negative patients. After an initial induction series of six vaccinations given once per month, patients will receive booster inoculations at two subsequent six-month intervals. The primary objectives are to measure the immune response, time to recurrence and overall survival between treatment arms.
- GALE-301 plus GM-CSF is an adjuvant treatment to prevent recurrences in high-risk ovarian and endometrial cancer patients rendered disease-free after completing standard-of-care therapy.
GALE-301 Phase 2a clinical trial enrollment complete
From other sites
at Zacks.com (Apr 9, 2015)
at Zacks.com (Mar 18, 2015)
at Zacks.com (Mar 9, 2015)
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs